Immunocore Holdings plc Payments of Debt Issuance Costs
Immunocore Holdings plc (IMCR) reported Payments of Debt Issuance Costs of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-25.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsOfDebtIssuanceCosts · last filed 2026-02-25
- Immunocore Holdings plc payments of debt issuance costs for the quarter ending 2025-12-31 was $0.00.
- Immunocore Holdings plc payments of debt issuance costs for the quarter ending 2025-09-30 was $0.00.
- Immunocore Holdings plc payments of debt issuance costs for the quarter ending 2025-06-30 was $0.00, a 100.00% decline year-over-year.
- Immunocore Holdings plc payments of debt issuance costs for the quarter ending 2025-03-31 was $0.00, a 100.00% decline year-over-year.
- Immunocore Holdings plc payments of debt issuance costs for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- Immunocore Holdings plc payments of debt issuance costs for fiscal 2024 was $13.36M.
- Immunocore Holdings plc payments of debt issuance costs for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- Immunocore Holdings plc payments of debt issuance costs for fiscal 2022 was $1.77M.
| Period end | Payments of Debt Issuance Costs 3 month | Payments of Debt Issuance Costs 6 month | Payments of Debt Issuance Costs 9 month | Payments of Debt Issuance Costs 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $0.00 derived: sum of 2 quarters · filed 2026-02-25 | $0.00 derived: sum of 3 quarters · filed 2026-02-25 | $0.00 10-K · filed 2026-02-25 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $0.00 derived: sum of 2 quarters · filed 2025-11-06 | $0.00 10-Q · filed 2025-11-06 | $0.00 derived: sum of 4 quarters · filed 2026-02-25 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $0.00 10-Q · filed 2025-08-07 | $0.00 derived: sum of 3 quarters · filed 2026-02-25 | $0.00 derived: sum of 4 quarters · filed 2026-02-25 |
| 2025-03-31 | $0.00 10-Q · filed 2025-05-07 | $0.00 derived: sum of 2 quarters · filed 2026-02-25 | $0.00 derived: sum of 3 quarters · filed 2026-02-25 | $1.12M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $0.00 derived: sum of 2 quarters · filed 2026-02-25 | $1.12M derived: sum of 3 quarters · filed 2026-02-25 | $13.36M 10-K · filed 2026-02-25 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $1.12M derived: sum of 2 quarters · filed 2025-11-06 | $13.36M 10-Q · filed 2025-11-06 | $13.36M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-06-30 | $1.12M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $13.36M 10-Q · filed 2025-08-07 | $13.36M derived: sum of 3 quarters · filed 2026-02-25 | $13.36M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-03-31 | $12.24M 10-Q · filed 2025-05-07 | $12.24M derived: sum of 2 quarters · filed 2026-02-25 | $12.24M derived: sum of 3 quarters · filed 2026-02-25 | $12.24M derived: sum of 4 quarters · filed 2026-02-25 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $0.00 derived: sum of 2 quarters · filed 2026-02-25 | $0.00 derived: sum of 3 quarters · filed 2026-02-25 | $0.00 10-K · filed 2026-02-25 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $0.00 derived: sum of 2 quarters · filed 2024-11-06 | $0.00 10-Q · filed 2024-11-06 | |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $0.00 10-Q · filed 2024-08-08 | ||
| 2023-03-31 | $0.00 10-Q · filed 2024-05-08 | |||
| 2022-12-31 | $1.77M 10-K · filed 2025-02-26 | |||
| 2021-12-31 | $0.00 10-K · filed 2024-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |